March 4 (Reuters) - Some U.S. stocks on the move on Monday:
Wall Street lower at the open as worries about the prospects for global economic growth prompted investors to step back from equities that are within reach of record highs. The Dow Jones industrial average was down 0.10 percent, the Standard & Poor’s 500 Index down 0.22 percent and the Nasdaq Composite Index down 0.33 percent.
** HESS CORP, $69.96, up 5 pct (0934 ET)
The oil and gas company will exit its retail, energy marketing and energy trading businesses following pressure from its third-largest shareholder - activist investor Elliott Management - to break up the company.
** MGIC INVESTMENT CORP, $4.20, up 11 pct (1001 ET)
The mortgage insurer’s stock continued its rally after gaining more than a fourth of its value on Friday.
Brokerage Keefe, Bruyette & Woods raised its price target on the MGIC stock to $4 from $1, while Susquehanna Financial Group reinstated its coverage on the stock with a “neutral” rating.
** STRATASYS INC, $72, up 12 pct (0933 ET)
The 3D printer maker’s fourth-quarter revenue handily beat analysts’ estimates and the company forecast 2013 revenue above Wall Street expectations.
** ARENA PHARMACEUTICALS INC, $8.07, down 3 pct (0936 ET)
The biopharmaceutical company reported a larger-than-expected quarterly loss as operating expenses rose.
** HECLA MINING CO, $4.16, down 10 pct (0935 ET)
** AURIZON MINES LTD, $4.42, up 5 pct (0936 ET)
** ALAMOS GOLD INC, $14.25, up 4 pct (0938 ET)
U.S. silver miner Hecla will buy Aurizon Mines for about C$796 million ($774 million) to gain control of a gold mine in Quebec, nearly a month after the Canadian company rejected an unsolicited offer from Alamos Gold.
** A. SCHULMAN INC, $31.64, up 2 pct (0939 ET)
** FERRO CORP, $6.61, up 27 pct (0940 ET)
Chemical maker A. Schulman offered to buy Ferro for $563 million nearly three weeks after being rebuffed by its rival, which makes products used in computers to mobile devices.
** APPLE INC, $426.23, down 1 pct (0942 ET)
Apple had a major setback in its ongoing mobile patents battle with Samsung Electronics on Friday, as a federal judge slashed a $1.05 billion jury award by more than 40 percent and set a new trial to determine damages.
** TRANSOCEAN LTD, $54.25, up 4 pct (0932 ET)
The world’s largest offshore drilling contractor said its board recommended restarting dividend payments, more than a month after activist investor Carl Icahn pushed for a payout.
The company reported on Friday a rise in revenue and a higher-than-expected profit for the fourth quarter as more of its fleet was working, compared with a year earlier.
** CELGENE CORP, $103.60, down 2 pct (0944 ET)
The company reported on Saturday late-stage study results of its drug apremilast, which aims to treat skin disease psoriasis.
“Overall, the efficacy was a bit below what was seen in the Phase II trial and appear (to) place apremilast below the Injectable biologics,” ISI Group analyst Mark Schoenebaum wrote in a note. However, he said the drug is “clearly approvable.”
“Even though apremilast’s efficacy is below biologics, we believe its good safety profile and the ease of oral administration could drive significant use,” Schoenebaum said.
** CENTRAL EUROPEAN DISTRIBUTION CORP, $0.66, up 10 pct (0947 ET)
A unit of Russia’s Alfa Group is interested in putting together a consortium to restructure one of the world’s largest vodka producers, Central European Distribution, according to a U.S. securities filing.
** GMX RESOURCES INC, $2.98, down 4 pct (0949 ET)
The oil and gas producer said it would fail to make an interest payment on its senior debt, due on Monday, without specifying a reason. It also said that its stock would be delisted from the New York Stock Exchange as its market capitalization was lower than $50 million for a 30-day trading period.
** YINGLI GREEN ENERGY, $2.22, down 7.5 pct (0950 ET)
Yingli Green, one of China’s largest solar equipment makers, reported its sixth straight quarterly loss as it wrote down the value of its inventory amid a four-year long slump in panel prices.
** DRAGONWAVE INC, $1.88, down 22 pct (0950 ET)
The telecom network equipment maker said revenue for the fourth quarter would miss its forecast, citing lower sales from the microwave technology business it bought from Nokia Siemens Networks last year.
** FEIHE INTERNATIONAL INC, $7.15, up 2 pct (0951 ET)
Feihe International, a maker of infant formula and milk powders, said it will merge with privately held Diamond Infant Formula Holding Ltd. Diamond Infant will acquire China’s Feihe for $7.40 per share.
** QUIDEL CORP, $23.17, down 4 pct (0945 ET)
Wedbush Securities cut its rating on the medical test maker to “underperform” from “neutral”, citing rising competition from peer Alere Inc.
** SAREPTA THERAPEUTICS INC, $30.62, up 4 pct (0945)
Sarepta said intramuscular administration of the company’s lead drug being studied as a treatment for the Marburg virus infection, a condition for which there are no drugs on the market, helped prolong the lives of all patients in a study. “This alternative delivery method to the intravenous route has the potential to greatly enhance the practical utility of (the drug) in a mass casualty situation,” the company said in a statement.
** PRANA BIOTECHNOLOGY LTD, $2.73, up 11 pct (0959 ET) The Australian drug developer said on Sunday it would present new data at an upcoming medical meeting showing its experimental drug PBT2 reduces brain cell damage caused by a particular protein associated with Alzheimer’s disease. The data will be presented at the 11th International Conference on Alzheimer’s and Parkinson’s Disease in Florence, Italy, from March 6 to 10. (Compiled by Chandni Doulatramani)